Chat
Procainamide and NAPA
Copy Utility
Optimize drug therapy and monitor patient adherence.
Immunoassay
Sun-Sat
Within 24 hours
Plain red. Also acceptable: Green (sodium heparin).
Separate serum from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Refrigerated.
EDTA plasma. Gray (sodium fluoride/potassium oxalate) or separator tubes or gels.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 6 months
| Test Number |
Components |
Reference Interval |
|---|---|---|
| N-acetylprocainamide (NAPA) | 6.0-20.0 µg/mL Toxic: 35.1 µg/mL or greater |
|
| Procainamide | 4.0-10.0 µg/mL Toxic: 12.1 µg/mL or greater |
The commonly expected therapeutic range for the sum of NAPA and Procainamide is 5-30 ug/mL. However, the concentration of NAPA is dependent on many factors, including; time of last procainamide dose, mode of administration, concomitant drug therapy, sample condition, time of sample collection and individual variations in absorption, biotransformation, distribution and excretion. Therapeutic ranges are provided only as a guide for interpretation along with other clinical symptoms and patient history.
FDA
80192
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0090175 | N-acetylprocainamide (NAPA) | 3834-9 |
| 0090235 | Procainamide | 3982-6 |
- N-Acetyl Procainamide
- NAPA
- Pronestyl
Feedback
